Business Intelligence for Pharmaceutical Companies
The recurring failure is not a lack of dashboards. It is that finance, commercial and the field each report a different number for the same month, and the meeting is spent reconciling rather than deciding. That is a definitions and lineage problem, and it is fixable.
In short
Hibridge builds commercial analytics and reporting for pharmaceutical companies — sales and market share dashboards, field-force performance, promotional response and channel attribution, territory and target optimisation, and forecasting. Work includes the data engineering underneath, so definitions are consistent and numbers reconcile between functions.
What we do
Commercial reporting that answers the question that was asked.
Commercial dashboards
Sales, market share, tender performance and portfolio view, with one agreed definition per metric and visible lineage.
Field-force analytics
Coverage, frequency, call quality and territory performance, reported in a way district managers can act on rather than only defend.
Promotional response and attribution
Connecting channel activity to prescribing or sales-out movement, with honest confidence intervals rather than implied precision.
Segmentation and targeting analytics
Prescriber potential models and call-plan optimisation, refreshed on a defined cycle rather than annually by habit.
Forecasting
Launch and in-market forecasting with documented assumptions and scenario ranges, so a forecast miss is diagnosable.
Data engineering
Pipelines, a governed metric layer, and quality monitoring — the part that determines whether any of the above is trusted.
Approach
How we build the reporting layer
01
Agree definitions
One written definition per metric, signed off across commercial, finance and medical before anything is built.
02
Build the layer
Pipelines and a governed semantic layer, so every dashboard draws on the same source.
03
Deliver views
Role-specific views — a district manager and a country lead do not need the same screen.
04
Sustain
Quality monitoring, a refresh cadence and an owner, so trust does not decay after month three.
Why it matters
Egypt’s payer mix is shifting as Universal Health Insurance rolls out governorate by governorate while more than half of health spending is still out of pocket. Commercial models built on last year’s payer assumptions go wrong quietly.
57.2%
World Bank / WHO Global Health Expenditure Database ·
3.13m
World Bank ·
Sources
Every figure on this page is attributed to its original publisher. Where a figure is organiser-reported or secondary, we say so.
Frequently asked questions
- What data sources do you work with?
- Syndicated market data where the client is subscribed, internal sales and CRM data, tender and public procurement records, and campaign platform data. We work with what is licensed to you; we do not resell third-party market data.
- Can you build on our existing BI platform?
- Yes. The platform is rarely the constraint. Most engagements are governance and data-model work delivered on the client’s existing tooling.
- Do you do forecasting for launch products with no historical data?
- Yes, using analogue-based approaches with the assumption set written down and scenario-ranged. The value is in making assumptions explicit enough to be challenged and revised.
Related services
Conference & Event Management
Congresses, symposia and advisory boards, run to pharma standards.
Conferences & EventsGo-To-Market & Product Launch
Launch sequencing built around what the market will actually reimburse.
Go-To-MarketPharmaceutical Marketing
HCP and patient programmes that survive review and move prescribing.
MarketingTell us what you are working on.
A launch, a congress, a portfolio that is not performing, or a compliance process that has become the bottleneck. We reply within one business day.